Levobunolol Hydrochloride Ophthalmic Solution USP, 0.5%, 5mL

NDC: 24208-505-05

Levobunolol Hydrochloride Ophthalmic Solution, USP 0.5%, 5 mL — Bausch + Lomb

Active ingredient	Levobunolol hydrochloride 0.5% (5 mg per mL)
Dosage form	Ophthalmic solution
Route	Topical ophthalmic
Size	5 mL
Manufacturer	Bausch + Lomb
NDC	24208-505-05

Indications and Usage

Lowers intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Dosage and Administration

Instill one to two drops of the 0.5% solution in the affected eye(s) once daily; may be increased to twice daily in patients with more severe or uncontrolled glaucoma. Dosages above one drop twice daily are not generally more effective.

Warnings and Precautions

• Systemically absorbed; may cause the same cardiac and respiratory adverse reactions as systemic beta-blockers, including bronchospasm and cardiac failure
• May mask signs of hypoglycemia in diabetics and symptoms of hyperthyroidism
• Consider gradual withdrawal before elective major surgery; discontinue at the first sign of cardiac failure
• May potentiate muscle weakness in myasthenic patients and potentiate vascular insufficiency syndromes (e.g., Raynaud's phenomenon); contains sodium metabisulfite, which may cause allergic-type reactions in susceptible individuals

Contraindications

Contraindicated in bronchial asthma or history of asthma, severe COPD, sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock, or hypersensitivity to any component.

Adverse Reactions

Transient ocular burning and stinging occur in up to 1 in 3 patients, and blepharoconjunctivitis in up to 1 in 20. Less frequent effects include headache, bradycardia, hypotension, and other cardiovascular events.

Storage and Handling

Store between 15°C to 25°C (59°F to 77°F). Protect from light. Replace cap immediately after use.

How Supplied

Sterile 0.5% ophthalmic solution in a plastic dropper bottle with controlled drop tip, including 5 mL size.

Professional use only. Clinical information summarized from FDA-approved prescribing information (Structured Product Labeling); refer to the full prescribing information via DailyMed for complete details.

If you have any questions related to DSCSA compliance, transaction history, regulatory data or quality assurance, please contact our team at compliance@dryeyerescue.com for more information.